PDS Biotechnology Corporation (NASDAQ:PDSB) Sees Large Decline in Short Interest

PDS Biotechnology Corporation (NASDAQ:PDSB) saw a large decrease in short interest in the month of March. As of March 13th, there was short interest totaling 2,035,289 shares, a decrease of 24.3% from the February 26th total of 2,688,806 shares. Approximately 4.3% of the shares of the stock are sold short. Based on an average daily volume of 221,785 shares, the days-to-cover ratio is presently 9.2 days.

PDS Biotechnology Stock Down 15.4%

Shares of NASDAQ PDSB opened at $0.54 on Friday. The firm has a market cap of $28.35 million, a price-to-earnings ratio of -0.66 and a beta of 1.20. The company’s 50-day simple moving average is $0.72 and its 200-day simple moving average is $0.86. The company has a quick ratio of 2.09, a current ratio of 2.09 and a debt-to-equity ratio of 1.26. PDS Biotechnology has a 52-week low of $0.52 and a 52-week high of $1.92.

Institutional Investors Weigh In On PDS Biotechnology

Several large investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new position in shares of PDS Biotechnology during the fourth quarter valued at approximately $25,000. Tempus Wealth Planning LLC increased its position in shares of PDS Biotechnology by 29.3% during the fourth quarter. Tempus Wealth Planning LLC now owns 61,800 shares of the company’s stock worth $48,000 after purchasing an additional 14,000 shares in the last quarter. Watts Gwilliam & Co. LLC purchased a new stake in shares of PDS Biotechnology during the second quarter worth approximately $73,000. Marshall Wace LLP acquired a new position in PDS Biotechnology in the 2nd quarter valued at $91,000. Finally, Jane Street Group LLC acquired a new position in PDS Biotechnology in the 2nd quarter valued at $92,000. 26.84% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of PDS Biotechnology in a report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $9.00.

About PDS Biotechnology

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.